deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02077881

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas

Sponsor: NewLink Genetics Corporation

Conditions Metastatic Pancreatic Adenocarcinoma Metastatic Pancreatic Cancer
Interventions Gemcitabine Indoximod Nab-Paclitaxel
Updated 13 times since 2017 Last updated: May 26, 2020 Started: Aug 31, 2014 Primary completion: Jan 17, 2018 Completion: Oct 17, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Metastatic Pancreatic Adenocarcinoma and Metastatic Pancreatic Cancer and is currently completed. NewLink Genetics Corporation leads this study, which shows 13 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Mar 2019 · 7 months · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Jun 2020 · 13 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 8 earlier versions

  1. Jun 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  2. May 2019 — Jun 2020 [monthly]

    Completed PHASE1_PHASE2

  3. Mar 2019 — May 2019 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  4. Aug 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NewLink Genetics Corporation
Data source: Lumos Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augusta, United States , Burlington, United States , Greenville, United States , Lexington, United States , Memphis, United States , Palo Alto, United States , Paramus, United States , Pittsburgh, United States , Salt Lake City, United States , Spartanburg, United States and 1 more location